TGTX Q4 2021 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+6007.9% YoY

Gross Profit

$2M91.0% margin

Operating Income

-$93M-4004.6% margin

Net Income

-$93M-4021.5% margin

EPS (Diluted)

$-0.70

QoQ Revenue Growth

+14.3%

Cash Flow

Operating Cash Flow

-$87M

Free Cash Flow

-$87M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$380M

Total Liabilities

$142M

Stockholders' Equity

$237M

Cash & Equivalents

$299M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$38,000	+6007.9%
Gross Profit	$2M	-$68,000	+3204.4%
Operating Income	-$93M	-$87M	-7.1%
Net Income	-$93M	-$88M	-5.8%

Revenue Segments

Product revenue, net

$2M98%

License revenue

$38,0002%